John P. Sharp is VP Finance and CFO at LIGAND PHARMACEUTICALS INC (LGND). They have made 6 open-market trades across 2 companies since 2013, most recently 2022-05-20.
CIK 0001342894
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $19K since 2018, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| PHAS | BUY | 2018-12-07 | 2018-12-11 | $3.84 | $19K | -22.0% | -6.2% | -24.9% |
| LGND | SELL | 2014-02-12 | 2014-02-14 | $74.74 | $6.5M | -9.9% | -3.4% | -3.4% |
| LGND | SELL | 2013-12-12 | 2013-12-16 | $53.44 | $37K | -9.9% | -3.4% | -3.4% |
| LGND | SELL | 2013-12-06 | 2013-12-09 | $56.08 | $336K | -9.9% | -3.4% | -3.4% |
| LGND | SELL | 2013-11-18 | 2013-11-20 | $53.00 | $60K | -9.9% | -3.4% | -3.4% |
| LGND | SELL | 2013-08-16 | 2013-08-20 | $42.75 | $321K | -9.9% | -3.4% | -3.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.